GILD - Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch | Benzinga
Saturday, Gilead Sciences Inc (NASDAQ:GILD), following the recent acquisition of CymaBay Therapeutics Inc, announced interim results from the ongoing ASSURE study.
The ASSURE study is an open-label study to evaluate the long-term safety and tolerability of seladelpar in people with primary biliary cholangitis (PBC) who have already participated in other PBC clinical trials of seladelpar. The study is currently enrolling up to 500 people.
Also Read: Gilead’s Aggressive Push Beyond HIV Treatments – Plans To Increase Cancer-Focused CAR-T Treatment Production.
The study demonstrated that the treatment with seladelpar led to improvements in markers of cholestasis and reduced inflammation.
Additional ...